315 related articles for article (PubMed ID: 33361611)
1. Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson's Disease.
Shrigley S; Nilsson F; Mattsson B; Fiorenzano A; Mudannayake J; Bruzelius A; Ottosson DR; Björklund A; Hoban DB; Parmar M
J Parkinsons Dis; 2021; 11(2):515-528. PubMed ID: 33361611
[TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
[TBL] [Abstract][Full Text] [Related]
3. Impact of α-synuclein pathology on transplanted hESC-derived dopaminergic neurons in a humanized α-synuclein rat model of PD.
Hoban DB; Shrigley S; Mattsson B; Breger LS; Jarl U; Cardoso T; Nelander Wahlestedt J; Luk KC; Björklund A; Parmar M
Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15209-15220. PubMed ID: 32541058
[TBL] [Abstract][Full Text] [Related]
4. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.
Sundberg M; Bogetofte H; Lawson T; Jansson J; Smith G; Astradsson A; Moore M; Osborn T; Cooper O; Spealman R; Hallett P; Isacson O
Stem Cells; 2013 Aug; 31(8):1548-62. PubMed ID: 23666606
[TBL] [Abstract][Full Text] [Related]
5. Identifying the optimal developmental age of human pluripotent stem cell-derived midbrain dopaminergic progenitors for transplantation in a rodent model of Parkinson's disease.
de Luzy IR; Pavan C; Moriarty N; Hunt CPJ; Vandenhoven Z; Khanna A; Niclis JC; Gantner CW; Thompson LH; Parish CL
Exp Neurol; 2022 Dec; 358():114219. PubMed ID: 36055392
[TBL] [Abstract][Full Text] [Related]
6. Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene.
Chen Y; Dolt KS; Kriek M; Baker T; Downey P; Drummond NJ; Canham MA; Natalwala A; Rosser S; Kunath T
Eur J Neurosci; 2019 Feb; 49(4):510-524. PubMed ID: 30472757
[TBL] [Abstract][Full Text] [Related]
7. Modeling Parkinson's disease using induced pluripotent stem cells.
Byers B; Lee HL; Reijo Pera R
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
[TBL] [Abstract][Full Text] [Related]
8. Cryopreservation of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurospheres for Clinical Application.
Hiramatsu S; Morizane A; Kikuchi T; Doi D; Yoshida K; Takahashi J
J Parkinsons Dis; 2022; 12(3):871-884. PubMed ID: 34958047
[TBL] [Abstract][Full Text] [Related]
9. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.
Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A
Cells; 2021 Sep; 10(9):. PubMed ID: 34572052
[TBL] [Abstract][Full Text] [Related]
10. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress.
Byers B; Cord B; Nguyen HN; Schüle B; Fenno L; Lee PC; Deisseroth K; Langston JW; Pera RR; Palmer TD
PLoS One; 2011; 6(11):e26159. PubMed ID: 22110584
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Human Primary with Human iPS Cell-Derived Dopaminergic Neuron Grafts in the Rat Model for Parkinson's Disease.
Peng SP; Copray S
Stem Cell Rev Rep; 2016 Feb; 12(1):105-20. PubMed ID: 26438376
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
Ganser C; Papazoglou A; Just L; Nikkhah G
Exp Cell Res; 2010 Mar; 316(5):737-46. PubMed ID: 20060824
[TBL] [Abstract][Full Text] [Related]
13. Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology.
Chang YL; Chen SJ; Kao CL; Hung SC; Ding DC; Yu CC; Chen YJ; Ku HH; Lin CP; Lee KH; Chen YC; Wang JJ; Hsu CC; Chen LK; Li HY; Chiou SH
Cell Transplant; 2012; 21(1):313-32. PubMed ID: 21669041
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats.
Cai J; Yang M; Poremsky E; Kidd S; Schneider JS; Iacovitti L
Stem Cells Dev; 2010 Jul; 19(7):1017-23. PubMed ID: 19824823
[TBL] [Abstract][Full Text] [Related]
15. Cell fate analysis of embryonic ventral mesencephalic grafts in the 6-OHDA model of Parkinson's disease.
Neto SC; Salti A; Puschban Z; Stefanova N; Nat R; Dechant G; Wenning GK
PLoS One; 2012; 7(11):e50178. PubMed ID: 23209667
[TBL] [Abstract][Full Text] [Related]
16. In Parkinson's patient-derived dopamine neurons, the triplication of α-synuclein locus induces distinctive firing pattern by impeding D2 receptor autoinhibition.
Lin M; Mackie PM; Shaerzadeh F; Gamble-George J; Miller DR; Martyniuk CJ; Khoshbouei H
Acta Neuropathol Commun; 2021 Jun; 9(1):107. PubMed ID: 34099060
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Phenotyping of Familial Parkinson's Disease with Human Induced Pluripotent Stem Cells: A Proof-of-Concept Study.
Zygogianni O; Antoniou N; Kalomoiri M; Kouroupi G; Taoufik E; Matsas R
Neurochem Res; 2019 Jun; 44(6):1475-1493. PubMed ID: 30989481
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9-Edited SNCA Knockout Human Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons and Their Vulnerability to Neurotoxicity.
Inoue S; Nishimura K; Gima S; Nakano M; Takata K
Biol Pharm Bull; 2023; 46(3):517-522. PubMed ID: 36858582
[TBL] [Abstract][Full Text] [Related]
19. Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons.
Zambon F; Cherubini M; Fernandes HJR; Lang C; Ryan BJ; Volpato V; Bengoa-Vergniory N; Vingill S; Attar M; Booth HDE; Haenseler W; Vowles J; Bowden R; Webber C; Cowley SA; Wade-Martins R
Hum Mol Genet; 2019 Jun; 28(12):2001-2013. PubMed ID: 30753527
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease.
Tamburrino A; Churchill MJ; Wan OW; Colino-Sanguino Y; Ippolito R; Bergstrand S; Wolf DA; Herz NJ; Sconce MD; Björklund A; Meshul CK; Decressac M
Acta Neuropathol Commun; 2015 Dec; 3():84. PubMed ID: 26666562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
